Abstract
We studied the therapeutic effect of high-dose administration of a thrombolytic agent (Abbokinase®) in 33 patients with sudden deafness.
The treated group received 120, 000IU of Abbokinase for 7 days and the results were compared with those in an untreated group.
In terms of clinical efficacy, the treated group showed 9 higher rate of recovery from sudden deafness than the untreated group.
Abbokinase was considered to effective in patients with sudden deafness.
